Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
15 Oct 2019
Historique:
received: 15 02 2019
revised: 29 05 2019
accepted: 19 07 2019
pubmed: 31 7 2019
medline: 2 6 2020
entrez: 31 7 2019
Statut: ppublish

Résumé

Chemotherapies alter cellular redox balance and reactive oxygen species (ROS) content. Recent studies have reported that chemoresistant cells have an increased oxidative state in hematologic malignancies. In this study, we demonstrated that chemoresistant acute myeloid leukemia (AML) cells had a lower level of mitochondrial and cytosolic ROS in response to cytarabine (AraC) and overexpressed myeloperoxidase (MPO), a heme protein that converts hydrogen peroxide to hypochlorous acid (HOCl), compared with sensitive AML cells. High MPO-expressing AML cells were less sensitive to AraC

Identifiants

pubmed: 31358527
pii: 0008-5472.CAN-19-0515
doi: 10.1158/0008-5472.CAN-19-0515
doi:

Substances chimiques

Antimetabolites, Antineoplastic 0
Neoplasm Proteins 0
RNA, Neoplasm 0
RNA, Small Interfering 0
Reactive Oxygen Species 0
Cytarabine 04079A1RDZ
Hypochlorous Acid 712K4CDC10
MPO protein, human EC 1.11.1.7
Peroxidase EC 1.11.1.7

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5191-5203

Informations de copyright

©2019 American Association for Cancer Research.

Auteurs

Mohsen Hosseini (M)

Centre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Equipe Labellisée LIGUE 2018, Toulouse, France.
University of Toulouse, Toulouse, France.

Hamid Reza Rezvani (HR)

INSERM U1035, Bordeaux, France.
Université de Bordeaux, Bordeaux, France.

Nesrine Aroua (N)

Centre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Equipe Labellisée LIGUE 2018, Toulouse, France.
University of Toulouse, Toulouse, France.

Claudie Bosc (C)

Centre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Equipe Labellisée LIGUE 2018, Toulouse, France.
University of Toulouse, Toulouse, France.

Thomas Farge (T)

Centre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Equipe Labellisée LIGUE 2018, Toulouse, France.
University of Toulouse, Toulouse, France.

Estelle Saland (E)

Centre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Equipe Labellisée LIGUE 2018, Toulouse, France.
University of Toulouse, Toulouse, France.

Véronique Guyonnet-Dupérat (V)

INSERM U1035, Bordeaux, France.
Université de Bordeaux, Bordeaux, France.

Sonia Zaghdoudi (S)

Centre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Equipe Labellisée LIGUE 2018, Toulouse, France.
University of Toulouse, Toulouse, France.

Latifa Jarrou (L)

Centre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Equipe Labellisée LIGUE 2018, Toulouse, France.
University of Toulouse, Toulouse, France.

Clément Larrue (C)

Centre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Equipe Labellisée LIGUE 2018, Toulouse, France.
University of Toulouse, Toulouse, France.

Marie Sabatier (M)

Centre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Equipe Labellisée LIGUE 2018, Toulouse, France.
University of Toulouse, Toulouse, France.

Pierre Luc Mouchel (PL)

Centre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Equipe Labellisée LIGUE 2018, Toulouse, France.
University of Toulouse, Toulouse, France.
Service d'Hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, CHU de Toulouse, Toulouse, France.

Mathilde Gotanègre (M)

Centre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Equipe Labellisée LIGUE 2018, Toulouse, France.
University of Toulouse, Toulouse, France.

Marc Piechaczyk (M)

Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Equipe Labellisée LIGUE, Montpellier, France.

Guillaume Bossis (G)

Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Equipe Labellisée LIGUE, Montpellier, France.

Christian Récher (C)

Centre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Equipe Labellisée LIGUE 2018, Toulouse, France.
University of Toulouse, Toulouse, France.
Service d'Hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, CHU de Toulouse, Toulouse, France.

Jean-Emmanuel Sarry (JE)

Centre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Equipe Labellisée LIGUE 2018, Toulouse, France. jean-emmanuel.sarry@inserm.fr.
University of Toulouse, Toulouse, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH